Outcome of Lower-Intensity Allogeneic Transplantation in Non-Hodgkin Lymphoma after Autologous Transplantation Failure

César O. Freytes, Mei Jie Zhang, Jeanette Carreras, Linda J. Burns, Robert Peter Gale, Luis Isola, Miguel Angel Perales, Matthew Seftel, Julie Marie Vose, Alan M. Miller, John Gibson, Thomas G. Gross, Philip A. Rowlings, David J. Inwards, Santiago Pavlovsky, Rodrigo Martino, David I. Marks, Gregory A. Hale, Sonali M. Smith, Harry C. Schouten & 5 others Simon Slavin, Thomas R. Klumpp, Hillard M. Lazarus, Koen van Besien, Parameswaran N. Hari

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

We studied the outcome of allogeneic hematopoietic stem cell transplantation after lower-intensity conditioning regimens (reduced-intensity conditioning and nonmyeloablative) in patients with non-Hodgkin lymphoma who relapsed after autologous hematopoietic stem cell transplantation. Nonrelapse mortality, lymphoma progression/relapse, progression-free survival (PFS), and overall survival were analyzed in 263 patients with non-Hodgkin lymphoma. All 263 patients had relapsed after a previous autologous hematopoietic stem cell transplantation and then had undergone allogeneic hematopoietic stem cell transplantation from a related (n = 26) or unrelated (n = 237) donor after reduced-intensity conditioning (n = 128) or nonmyeloablative (n = 135) and were reported to the Center for International Blood and Marrow Transplant Research between 1996 and 2006. The median follow-up of survivors was 68 months (range, 3-111 months). Three-year nonrelapse mortality was 44% (95% confidence interval [CI], 37%-50%). Lymphoma progression/relapse at 3 years was 35% (95% CI, 29%-41%). Three-year probabilities of PFS and overall survival were 21% (95% CI, 16%-27%) and 32% (95% CI, 27%-38%), respectively. Superior Karnofsky Performance Score, longer interval between transplantations, total body irradiation-based conditioning regimen, and lymphoma remission at transplantation were correlated with improved PFS. Allogeneic hematopoietic stem cell transplantation after lower-intensity conditioning is associated with significant nonrelapse mortality but can result in long-term PFS. We describe a quantitative risk model based on pretransplantation risk factors to identify those patients likely to benefit from this approach.

Original languageEnglish (US)
Pages (from-to)1255-1264
Number of pages10
JournalBiology of Blood and Marrow Transplantation
Volume18
Issue number8
DOIs
StatePublished - Aug 1 2012

Fingerprint

Autologous Transplantation
Hematopoietic Stem Cell Transplantation
Homologous Transplantation
Non-Hodgkin's Lymphoma
Disease-Free Survival
Confidence Intervals
Lymphoma
Mortality
Transplantation
Recurrence
Survival
Whole-Body Irradiation
Survivors
Bone Marrow
Tissue Donors
Transplants
Research

Keywords

  • Allogeneic
  • Reduced-intensity
  • Relapse

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Outcome of Lower-Intensity Allogeneic Transplantation in Non-Hodgkin Lymphoma after Autologous Transplantation Failure. / Freytes, César O.; Zhang, Mei Jie; Carreras, Jeanette; Burns, Linda J.; Gale, Robert Peter; Isola, Luis; Perales, Miguel Angel; Seftel, Matthew; Vose, Julie Marie; Miller, Alan M.; Gibson, John; Gross, Thomas G.; Rowlings, Philip A.; Inwards, David J.; Pavlovsky, Santiago; Martino, Rodrigo; Marks, David I.; Hale, Gregory A.; Smith, Sonali M.; Schouten, Harry C.; Slavin, Simon; Klumpp, Thomas R.; Lazarus, Hillard M.; van Besien, Koen; Hari, Parameswaran N.

In: Biology of Blood and Marrow Transplantation, Vol. 18, No. 8, 01.08.2012, p. 1255-1264.

Research output: Contribution to journalArticle

Freytes, CO, Zhang, MJ, Carreras, J, Burns, LJ, Gale, RP, Isola, L, Perales, MA, Seftel, M, Vose, JM, Miller, AM, Gibson, J, Gross, TG, Rowlings, PA, Inwards, DJ, Pavlovsky, S, Martino, R, Marks, DI, Hale, GA, Smith, SM, Schouten, HC, Slavin, S, Klumpp, TR, Lazarus, HM, van Besien, K & Hari, PN 2012, 'Outcome of Lower-Intensity Allogeneic Transplantation in Non-Hodgkin Lymphoma after Autologous Transplantation Failure', Biology of Blood and Marrow Transplantation, vol. 18, no. 8, pp. 1255-1264. https://doi.org/10.1016/j.bbmt.2011.12.581
Freytes, César O. ; Zhang, Mei Jie ; Carreras, Jeanette ; Burns, Linda J. ; Gale, Robert Peter ; Isola, Luis ; Perales, Miguel Angel ; Seftel, Matthew ; Vose, Julie Marie ; Miller, Alan M. ; Gibson, John ; Gross, Thomas G. ; Rowlings, Philip A. ; Inwards, David J. ; Pavlovsky, Santiago ; Martino, Rodrigo ; Marks, David I. ; Hale, Gregory A. ; Smith, Sonali M. ; Schouten, Harry C. ; Slavin, Simon ; Klumpp, Thomas R. ; Lazarus, Hillard M. ; van Besien, Koen ; Hari, Parameswaran N. / Outcome of Lower-Intensity Allogeneic Transplantation in Non-Hodgkin Lymphoma after Autologous Transplantation Failure. In: Biology of Blood and Marrow Transplantation. 2012 ; Vol. 18, No. 8. pp. 1255-1264.
@article{966ffb4b8aae4fffaf1945d9eb878c5c,
title = "Outcome of Lower-Intensity Allogeneic Transplantation in Non-Hodgkin Lymphoma after Autologous Transplantation Failure",
abstract = "We studied the outcome of allogeneic hematopoietic stem cell transplantation after lower-intensity conditioning regimens (reduced-intensity conditioning and nonmyeloablative) in patients with non-Hodgkin lymphoma who relapsed after autologous hematopoietic stem cell transplantation. Nonrelapse mortality, lymphoma progression/relapse, progression-free survival (PFS), and overall survival were analyzed in 263 patients with non-Hodgkin lymphoma. All 263 patients had relapsed after a previous autologous hematopoietic stem cell transplantation and then had undergone allogeneic hematopoietic stem cell transplantation from a related (n = 26) or unrelated (n = 237) donor after reduced-intensity conditioning (n = 128) or nonmyeloablative (n = 135) and were reported to the Center for International Blood and Marrow Transplant Research between 1996 and 2006. The median follow-up of survivors was 68 months (range, 3-111 months). Three-year nonrelapse mortality was 44{\%} (95{\%} confidence interval [CI], 37{\%}-50{\%}). Lymphoma progression/relapse at 3 years was 35{\%} (95{\%} CI, 29{\%}-41{\%}). Three-year probabilities of PFS and overall survival were 21{\%} (95{\%} CI, 16{\%}-27{\%}) and 32{\%} (95{\%} CI, 27{\%}-38{\%}), respectively. Superior Karnofsky Performance Score, longer interval between transplantations, total body irradiation-based conditioning regimen, and lymphoma remission at transplantation were correlated with improved PFS. Allogeneic hematopoietic stem cell transplantation after lower-intensity conditioning is associated with significant nonrelapse mortality but can result in long-term PFS. We describe a quantitative risk model based on pretransplantation risk factors to identify those patients likely to benefit from this approach.",
keywords = "Allogeneic, Reduced-intensity, Relapse",
author = "Freytes, {C{\'e}sar O.} and Zhang, {Mei Jie} and Jeanette Carreras and Burns, {Linda J.} and Gale, {Robert Peter} and Luis Isola and Perales, {Miguel Angel} and Matthew Seftel and Vose, {Julie Marie} and Miller, {Alan M.} and John Gibson and Gross, {Thomas G.} and Rowlings, {Philip A.} and Inwards, {David J.} and Santiago Pavlovsky and Rodrigo Martino and Marks, {David I.} and Hale, {Gregory A.} and Smith, {Sonali M.} and Schouten, {Harry C.} and Simon Slavin and Klumpp, {Thomas R.} and Lazarus, {Hillard M.} and {van Besien}, Koen and Hari, {Parameswaran N.}",
year = "2012",
month = "8",
day = "1",
doi = "10.1016/j.bbmt.2011.12.581",
language = "English (US)",
volume = "18",
pages = "1255--1264",
journal = "Biology of Blood and Marrow Transplantation",
issn = "1083-8791",
publisher = "Elsevier Inc.",
number = "8",

}

TY - JOUR

T1 - Outcome of Lower-Intensity Allogeneic Transplantation in Non-Hodgkin Lymphoma after Autologous Transplantation Failure

AU - Freytes, César O.

AU - Zhang, Mei Jie

AU - Carreras, Jeanette

AU - Burns, Linda J.

AU - Gale, Robert Peter

AU - Isola, Luis

AU - Perales, Miguel Angel

AU - Seftel, Matthew

AU - Vose, Julie Marie

AU - Miller, Alan M.

AU - Gibson, John

AU - Gross, Thomas G.

AU - Rowlings, Philip A.

AU - Inwards, David J.

AU - Pavlovsky, Santiago

AU - Martino, Rodrigo

AU - Marks, David I.

AU - Hale, Gregory A.

AU - Smith, Sonali M.

AU - Schouten, Harry C.

AU - Slavin, Simon

AU - Klumpp, Thomas R.

AU - Lazarus, Hillard M.

AU - van Besien, Koen

AU - Hari, Parameswaran N.

PY - 2012/8/1

Y1 - 2012/8/1

N2 - We studied the outcome of allogeneic hematopoietic stem cell transplantation after lower-intensity conditioning regimens (reduced-intensity conditioning and nonmyeloablative) in patients with non-Hodgkin lymphoma who relapsed after autologous hematopoietic stem cell transplantation. Nonrelapse mortality, lymphoma progression/relapse, progression-free survival (PFS), and overall survival were analyzed in 263 patients with non-Hodgkin lymphoma. All 263 patients had relapsed after a previous autologous hematopoietic stem cell transplantation and then had undergone allogeneic hematopoietic stem cell transplantation from a related (n = 26) or unrelated (n = 237) donor after reduced-intensity conditioning (n = 128) or nonmyeloablative (n = 135) and were reported to the Center for International Blood and Marrow Transplant Research between 1996 and 2006. The median follow-up of survivors was 68 months (range, 3-111 months). Three-year nonrelapse mortality was 44% (95% confidence interval [CI], 37%-50%). Lymphoma progression/relapse at 3 years was 35% (95% CI, 29%-41%). Three-year probabilities of PFS and overall survival were 21% (95% CI, 16%-27%) and 32% (95% CI, 27%-38%), respectively. Superior Karnofsky Performance Score, longer interval between transplantations, total body irradiation-based conditioning regimen, and lymphoma remission at transplantation were correlated with improved PFS. Allogeneic hematopoietic stem cell transplantation after lower-intensity conditioning is associated with significant nonrelapse mortality but can result in long-term PFS. We describe a quantitative risk model based on pretransplantation risk factors to identify those patients likely to benefit from this approach.

AB - We studied the outcome of allogeneic hematopoietic stem cell transplantation after lower-intensity conditioning regimens (reduced-intensity conditioning and nonmyeloablative) in patients with non-Hodgkin lymphoma who relapsed after autologous hematopoietic stem cell transplantation. Nonrelapse mortality, lymphoma progression/relapse, progression-free survival (PFS), and overall survival were analyzed in 263 patients with non-Hodgkin lymphoma. All 263 patients had relapsed after a previous autologous hematopoietic stem cell transplantation and then had undergone allogeneic hematopoietic stem cell transplantation from a related (n = 26) or unrelated (n = 237) donor after reduced-intensity conditioning (n = 128) or nonmyeloablative (n = 135) and were reported to the Center for International Blood and Marrow Transplant Research between 1996 and 2006. The median follow-up of survivors was 68 months (range, 3-111 months). Three-year nonrelapse mortality was 44% (95% confidence interval [CI], 37%-50%). Lymphoma progression/relapse at 3 years was 35% (95% CI, 29%-41%). Three-year probabilities of PFS and overall survival were 21% (95% CI, 16%-27%) and 32% (95% CI, 27%-38%), respectively. Superior Karnofsky Performance Score, longer interval between transplantations, total body irradiation-based conditioning regimen, and lymphoma remission at transplantation were correlated with improved PFS. Allogeneic hematopoietic stem cell transplantation after lower-intensity conditioning is associated with significant nonrelapse mortality but can result in long-term PFS. We describe a quantitative risk model based on pretransplantation risk factors to identify those patients likely to benefit from this approach.

KW - Allogeneic

KW - Reduced-intensity

KW - Relapse

UR - http://www.scopus.com/inward/record.url?scp=84864017956&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84864017956&partnerID=8YFLogxK

U2 - 10.1016/j.bbmt.2011.12.581

DO - 10.1016/j.bbmt.2011.12.581

M3 - Article

VL - 18

SP - 1255

EP - 1264

JO - Biology of Blood and Marrow Transplantation

JF - Biology of Blood and Marrow Transplantation

SN - 1083-8791

IS - 8

ER -